<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="17754">Glycerol</z:chebi> is a potent osmotic dehydrating agent with additional effects on brain metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>In doses of 0.25-2.0 g/kg <z:chebi fb="3" ids="17754">glycerol</z:chebi> decreases intracranial pressure in numerous <z:mp ids='MP_0002054'>disease states</z:mp>, including <z:e sem="disease" ids="C0035400" disease_type="Disease or Syndrome" abbrv="">Reye's syndrome</z:e>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0002383'>encephalitis</z:hpo>, <z:hpo ids='HP_0001287'>meningitis</z:hpo>, <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e>, central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, and space occupying lesions </plain></SENT>
<SENT sid="2" pm="."><plain>It is also effective in lowering intraocular pressure in <z:hpo ids='HP_0000501'>glaucoma</z:hpo> and shrinking the brain during neurosurgical procedures </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0268009" disease_type="Disease or Syndrome" abbrv="">Hyperosmolality</z:e> with rebound cerebral overhydration is of concern, especially in patients with altered blood brain barriers </plain></SENT>
<SENT sid="4" pm="."><plain>They may be avoided if <z:chebi fb="3" ids="17754">glycerol</z:chebi> is administered on an intermittent rather than a continuous basis </plain></SENT>
<SENT sid="5" pm="."><plain>Intravascular <z:mp ids='MP_0010163'>hemolysis</z:mp> does not occur with oral use </plain></SENT>
<SENT sid="6" pm="."><plain>When administered intravenously, <z:mp ids='MP_0010163'>hemolysis</z:mp> can be minimized by using <z:chebi fb="3" ids="17754">glycerol</z:chebi> 10% in <z:chebi fb="10" ids="4167">dextrose</z:chebi> 5% with <z:mpath ids='MPATH_458'>normal</z:mpath> saline at rates of 6 mg/kg/min or less </plain></SENT>
<SENT sid="7" pm="."><plain>However, intravenous doses of 1-2 g/kg every 2 hr can be administered safely in severe cases of elevated ICP </plain></SENT>
<SENT sid="8" pm="."><plain>In such patients, <z:chebi fb="3" ids="17754">glycerol</z:chebi> serum concentration, serum osmolality and ICP monitoring are required to optimize <z:chebi fb="3" ids="17754">glycerol</z:chebi> therapy </plain></SENT>
</text></document>